Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Marmara Pharmaceutical Journal 2010 , Vol 14 , Issue 1
Investigation of the prevalance of extended spectrum beta lactamase producing escherichia coli strains isolated from various clinical specimens
Müjde Eryılmaz1, Merve Eylül Bozkurt1, Muharrem Murat Yıldız2, Ahmet Akın1
1Ankara Üniversitesi Eczacılık Fakültesi, Farmasötik Mikrobiyoloji AD, Ankara, Türkiye
2Etlik Lokman Hekim Hastanesi, Ankara, Türkiye
DOI : 10.12991/201014459 Infections caused by Escherichia coli (E.coli) producing extended-spectrum beta lactamase (ESBL) are important because they are difficult to treat, have high mortality rate and cause big economic losses. In this study, prevalence of ESBL production in 114 E.coli strains, isolated from various clinical specimens at Lokman Hekim Hospital between September 2008-April 2009 was observed. The production of ESBL was determined with double disc synergy test and phenotypic confirmation test according to the Clinical Laboratory Standards Institute (CLSI) guidelines. The prevalence of ESBL producing E.coli isolates was found to be 18,42%. The results of the studies on prevalence of ESBL positive E.coli strains will be helpful for using antimicrobials in empiric treatment. Keywords : double disc synergy test, Escherichia coli, extended spectrum beta-lactamase
Marmara University